Full Press Release Details
Secures Suppliers for COVID-style hMPV Outbreak
WOBURN, Mass., Jan. 16, 2025 (Newsfile Corp.) -- iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, has secured suppliers for the flu-like
human metapneumovirus (hMPV). The virus has been causing hospitals in China to become overrun, raising the potential for another COVID-style
pandemic. iSpecimen is a market leader in the biospecimen space and leverages its vast network of suppliers to procure specimens for
the anticipated potential demand that may come with the need to study this disease and develop a vaccine to address it.
Human metapneumovirus
(hMPV) is a virus which causes upper respiratory infections. While those infected with hMPV typically present with only mild symptoms,
it can make some people very sick and cause death in the elderly, immunocompromised, and those with chronic conditions. There is currently
no vaccine for HMPV, hence the potential need for samples if a company were looking to make this type of breakthrough drug or study the
With the devastation
of COVID 5 years ago, there is concern in some areas that the virus could cause similar problems as it spreads in a very similar fashion
through respiratory droplets from coughing or sneezing, close personal contact and touching contaminated surfaces before contacting the
mouth, nose, or eyes. HMPV is very difficult to differentiate from COVID-19, flu, and respiratory syncytial virus (RSV), and unlike these
viruses there is no vaccine for HMPV.
The potential demand
for hMPV specimens continues to grow as hMPV remains a significant area of attention in the news and concern among the general population.
The potential demand for a vaccine for this fast spreading disease highlights the critical need for reliable access to high-quality specimens.
iSpecimen is poised to address this need through its strategic global partnerships with high value suppliers and streamlining of specimen
ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare
providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists
to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other
healthcare organizations. For more information, please visit www.ispecimen.com.
Forward Looking Statements
may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such
as "may," "will," "expect," "intend," "anticipate," "believe,"
"estimate" and "continue" or similar words. You should read statements that contain these words carefully because
they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state
other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that
are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause
actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the
risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements
speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict
those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking
statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in
the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the
Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information,
future events or otherwise.
For further information, please contact: